-
Hoechst 33342 for TNT Transport Imaging Workflows
2026-09-24
Use Hoechst 33342 to add nuclear and cell-boundary context to live-cell studies of lipid-droplet transport through tunneling nanotubes—without mistaking a nuclear stain for a cargo or force reporter. This workflow pairs practical staining guidance with the optical-trapping findings that explain what a complementary nuclear channel can, and cannot, reveal.
-
Eudragit-Coated LNPs for Oral RNA Delivery
2026-09-24
Haque, Shrestha, and Mattheolabakis investigated whether a pH-sensitive Eudragit S 100 coating could protect lipid nanoparticles and their RNA cargo during gastrointestinal transit. The in vitro results support a formulation strategy for oral RNA delivery, while leaving in vivo absorption and efficacy to be established.
-
CDK4/6–BET Synergy in Pancreatic Cancer
2026-09-23
Gu et al. show that CDK4/6 inhibition can restrain pancreatic tumor cell proliferation while simultaneously enhancing migration, invasion, and epithelial-to-mesenchymal transition. Their study identifies BET inhibition as a complementary strategy that restores antitumor activity through coordinated regulation of GSK3β-mediated Wnt/β-catenin signaling and TGF-β/Smad pathway crosstalk.
-
Tunable Human Intestinal Organoids: Study Insights
2026-09-23
Yang and colleagues developed a human small-intestinal organoid system that maintains strong proliferation while expanding cellular diversity under a unified culture condition. The study shows that reinforcing stemness can increase, rather than suppress, differentiation potential, while BET, Wnt, Notch, and BMP pathway modulation enables reversible or directional control of intestinal cell fate.
-
Gepotidacin (GSK2140944) Research Workflows
2026-09-22
Build stronger antibacterial research workflows around Gepotidacin, from DMSO stock preparation and MIC testing to topoisomerase assays and resistance profiling. Quantitative product data and a phase 2 gonorrhea study help connect mechanistic readouts with practical assay decisions while preserving research-use boundaries.
-
Bafilomycin C1 for High-Content Cardiotoxicity Assays
2026-09-21
Bafilomycin C1 connects lysosomal acidification control with high-content phenotyping, helping researchers distinguish autophagic flux effects from generalized cytotoxicity. This practical workflow adapts lessons from iPSC-cardiomyocyte deep-learning screens while keeping dose selection, imaging, and interpretation experimentally disciplined.
-
ABT-199: Mapping BCL-2 Dependence in Cell Death
2026-09-21
ABT-199, also known as Venetoclax, is a highly selective BCL-2 inhibitor for dissecting mitochondrial apoptosis and therapy-resistant cell states. This article translates its molecular selectivity into practical assay design, with special attention to senescent glioblastoma models and hematologic malignancy research.
-
Saquinavir: Permeability and HIV Protease Workflows
2026-09-20
Saquinavir supports complementary workflows that connect HIV protease target engagement with membrane-partitioning and permeability measurements. This practical guide translates recent biomimetic chromatography findings into assay setup, optimization, and troubleshooting decisions for antiretroviral drug research.
-
HABA for Reliable Biotinylation Assays
2026-09-19
This scenario-driven guide explains how HABA (4′-Hydroxyazobenzene-2-carboxylic acid), SKU B7918, can improve biotin-accessibility measurements in workflows involving cell assays, avidin or streptavidin, and functionalized PLGA particles. It separates HABA-based biochemical readouts from direct viability, proliferation, cytotoxicity, drug-release, and tissue-penetration measurements.
-
Gepotidacin vs Nitrofurantoin in UTI Trials
2026-09-19
The EAGLE-2 and EAGLE-3 phase 3 trials evaluated oral gepotidacin against nitrofurantoin for uncomplicated urinary tract infection using a rigorous double-blind, double-dummy non-inferiority design. Gepotidacin was non-inferior in both studies and superior in EAGLE-3, supporting further evaluation of a first-in-class antibacterial approach for infections affected by resistance to established agents.
-
WP1066 and the JAK2/STAT3 Translational Pivot
2026-09-18
WP1066 offers a cell-permeable way to interrogate JAK2/STAT3 pathway dependence across oncology models while sharpening interpretation of emerging immunoregenerative studies. This thought-leadership guide connects pathway biology, assay design, translational strategy, and the limitations of moving an inhibitory tool from cancer research into bone-repair research.
-
Phosbind Biotin for Protein Phosphorylation
2026-09-18
Phosbind Biotin provides sequence-independent detection of phosphorylated proteins on PVDF, making it useful when phospho-specific antibodies are unavailable or poorly validated. This practical workflow applies the reagent to PtrbZIP12-centered drought research while emphasizing controls, buffer selection, and troubleshooting.
-
Phosphatase Inhibitor Cocktail 3 Workflow Guide
2026-09-17
Protect phosphorylation-dependent signals from the moment a sample is lysed through Western blotting, co-immunoprecipitation, and kinase assays. This workflow guide shows how Phosphatase Inhibitor Cocktail 3 supports protein phosphorylation preservation while translating mechanistic insights from hepatic autophagy research into practical assay design.
-
Fe3O4@ZIF-8 for Jaw Osteomyelitis: Study Analysis
2026-09-17
This 2026 study develops pH-responsive Fe3O4@ZIF-8 core–shell nanoparticles that combine Zn2+-mediated antibacterial activity with Fe3O4- and magnetic-field-assisted bone regeneration. Its central contribution is a single platform designed to address both persistent infection and infected jaw-bone defects, although further work is needed to establish long-term safety and clinical transferability.
-
Talabostat mesylate: FAP and DPP4 Workflows
2026-09-16
Talabostat mesylate, also called PT-100, provides a practical pharmacological tool for separating DPP4- and FAP-dependent biology in tumor and immune-cell models. This guide emphasizes matched FAP-positive and FAP-negative assays, enzyme-inhibition controls, solution handling, and interpretation alongside FAP-activated vascular-disruption research.